BCRX BIOCRYST PHARMACEUTICALS INC
FY2025 10-K
BIOCRYST PHARMACEUTICALS INC (BCRX) filed its fiscal year 2025 10-K annual report with the SEC on Feb 26, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business model: Biopharmaceutical company focused on development and commercialization of pharmaceutical products, including rare disease treatments like ORLADEYO
- • Strategic shift: Sale of European ORLADEYO business with a Global Brand and Support Agreement limiting sole control over European brand positioning
Management Discussion & Analysis
- • No revenue or YoY change figures provided in the MD&A section
- • No specific profitability or margin % data disclosed
Risk Factors
- • FDA approval of ORLADEYO oral pellet for pediatric HAE patients aged 2 to <12 years in December 2025
- • Revenues from European ORLADEYO business divested in October 2025 for $254.5M cash proceeds
Financial SummaryXBRL
Revenue
$875M
Net Income
$264M
Operating Margin
39.0%
Net Margin
30.2%
ROE
-221.4%
Total Assets
$514M
EPS (Diluted)
$1.21
Operating Cash Flow
$347M
Source: XBRL data from BIOCRYST PHARMACEUTICALS INC FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on BIOCRYST PHARMACEUTICALS INC
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.